Compare GSL & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | DBVT |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Greece | France |
| Employees | 11 | 90 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2014 |
| Metric | GSL | DBVT |
|---|---|---|
| Price | $37.40 | $19.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $43.50 | $31.75 |
| AVG Volume (30 Days) | ★ 389.8K | 193.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,151,000.00 |
| Revenue This Year | N/A | $65.50 |
| Revenue Next Year | N/A | $47.02 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.73 | $3.91 |
| 52 Week High | $41.40 | $26.19 |
| Indicator | GSL | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 42.40 |
| Support Level | $36.67 | $8.55 |
| Resistance Level | $38.52 | $25.00 |
| Average True Range (ATR) | 1.26 | 1.54 |
| MACD | -0.34 | -0.21 |
| Stochastic Oscillator | 16.49 | 22.70 |
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.